

Synthetic Study of Azaspiracid-1: Synthesis of the EFGHI-Ring Fragment


Masato Oikawa,* Tomoko Uehara, Taizo Iwayama, and Makoto Sasaki*

Laboratory of Biostructural Chemistry, Graduate School of Life Sciences, Tohoku University, Tsutsumidori-amamiya, Aoba-ku, Sendai 981-8555, Japan

mao@bios.tohoku.ac.jp

Received June 6, 2006

ABSTRACT



Here, we report a synthesis of the lower half C₂₁–C₄₀ fragment of the shellfish toxin, azaspiracid-1. The C₂₈–C₄₀ fragment was synthesized by a coupling between the C₂₈–C₃₅ epoxide and the C₃₆–C₄₀ dithioacetal anion, followed by the HI-ring spiroaminal formation. An aldehyde corresponding to the C₂₈–C₄₀ fragment was then coupled with the C₂₁–C₂₇ allylic stannane by using InCl₃. Finally, the FG-ring was constructed by HF-pyridine to accomplish the synthesis of the suitably protected C₂₁–C₄₀ fragment.

Azaspiracid-1 (**1**) is a causative toxin for a new type of shellfish poisoning syndrome named azaspiracid poisoning (AZP), which has prevailed since November 1995 at a coastal region in Europe.¹ The structure was first elucidated spectroscopically by a group led by Yasumoto and Satake at Tohoku University in 1998 by using contaminated Irish mussels, *Mytilus edulis*.² The structural characteristics are (1) a C₆–C₁₇ bispiroketal fused to a C₁₇–C₂₀ tetrahydrofuran and (2) an unusual C₃₃–C₄₀ azaspiro ring fused with C₂₈–C₄₀ 2,9-dioxabicyclo[3.3.1]nonane. Four congeners, azaspiracids-2–5, were found by the same group thereafter,³ and the lethality against mice (LD₅₀) was found to be nearly comparable to that of **1** (0.2 mg/kg) for azaspiracids-2–4 (0.11–0.47 mg/kg) and less toxic for azaspiracid-5 (> 1 mg/kg).⁴

Since the first publication on **1**,² synthetic studies have been actively developed by many groups, and the first total synthesis and the structural revision of **1** were made by the Nicolaou group in 2004 by a strategy synthesizing possible combinations of partial structures.⁵ Recently, the Nicolaou group also synthesized azaspiracid-2 and -3, confirming the revised structure for these congeners.⁶ We have been working toward the total synthesis of **1** to clarify the molecular mechanism of AZP toward humans.⁷ Here, we describe our

(4) Ofuji, K.; Satake, M.; Oshima, Y.; Naoki, H.; Yasumoto, T. In *43rd Symposium on the Chemistry of Natural Products*; Osaka, 2001; p 353.

(5) For the whole story for the structural revision of **1**, see: (a) Freemantle, M. *Chem. Eng. News* **2004**, 82, 27. (b) Nicolaou, K. C.; Vyskocil, S.; Koftis, T. V.; Yamada, Y. M. A.; Ling, T. T.; Chen, D. Y. K.; Tang, W. J.; Petrovic, G.; Frederick, M. O.; Li, Y. W.; Satake, M. *Angew. Chem., Int. Ed.* **2004**, 43, 4312. (c) Nicolaou, K. C.; Koftis, T. V.; Vyskocil, S.; Petrovic, G.; Ling, T. T.; Yamada, Y. M. A.; Tang, W. J.; Frederick, M. O. *Angew. Chem., Int. Ed.* **2004**, 43, 4318. (d) Nicolaou, K. C.; Pihko, P. M.; Bernal, F.; Frederick, M. O.; Qian, W. Y.; Uesaka, N.; Diedrichs, N.; Hinrichs, J.; Koftis, T. V.; Loizidou, E.; Petrovic, G.; Rodriguez, M.; Sarlah, D.; Zou, N. *J. Am. Chem. Soc.* **2006**, 128, 2244. (e) Nicolaou, K. C.; Chen, D. Y. K.; Li, Y. W.; Uesaka, N.; Petrovic, G.; Koftis, T. V.; Bernal, F.; Frederick, M. O.; Govindasamy, M.; Ling, T. T.; Pihko, P. M.; Tang, W. J.; Vyskocil, S. *J. Am. Chem. Soc.* **2006**, 128, 2258. (f) Nicolaou, K. C.; Koftis, T. V.; Vyskocil, S.; Petrovic, G.; Tang, W. J.; Frederick, M. O.; Chen, D. Y. K.; Li, Y. W.; Ling, T. T.; Yamada, Y. M. A. *J. Am. Chem. Soc.* **2006**, 128, 2859.

(1) (a) McMahon, T.; Silke, J. *Harmful Algae News* **1996**, 14, 2. (b) James, K. J.; Furey, A.; Lehane, M.; Ramstad, H.; Aune, T.; Hovgaard, P.; Morris, S.; Higman, W.; Satake, M.; Yasumoto, T. *Toxicon* **2002**, 40, 909.


(2) Satake, M.; Ofuji, K.; Naoki, H.; James, K. J.; Furey, A.; McMahon, T.; Silke, J.; Yasumoto, T. *J. Am. Chem. Soc.* **1998**, 120, 9967.

(3) (a) Ofuji, K.; Satake, M.; McMahon, T.; Silke, J.; James, K. J.; Naoki, H.; Oshima, Y.; Yasumoto, T. *Nat. Toxins* **1999**, 7, 99. (b) Ofuji, K.; Satake, M.; McMahon, T.; James, K. J.; Naoki, H.; Oshima, Y.; Yasumoto, T. *Biosci. Biotechnol. Biochem.* **2001**, 65, 740.

efforts toward this goal and the synthesis of the C₂₁–C₄₀ EFGHI-ring fragment **2**, the lower half of **1**.⁸

Our synthetic plan toward azaspiracid-1 (**1**) is shown in Scheme 1. Retrosynthetic disconnection at the C₂₀–C₂₁ bond


Scheme 1. Synthetic Strategy for Azaspiracid-1 (**1**)



generates two C₁–C₂₀ and C₂₁–C₄₀ (**2**) fragments. These fragments would be assembled by the coupling between a benzotriazole amide and a sulfonylpyran, also employed in the synthesis of altohyrtin C by Evans et al.⁹ The C₂₁–C₄₀ EFGHI-ring fragment **2** was further divided retrosynthetically into two fragments, corresponding to the C₂₁–C₂₇ E-ring (**3**) and the C₂₈–C₄₀ FGHI-ring (**4**) domains, which were to be coupled by the reaction between an aldehyde and an allylic stannane under mild conditions.

The synthesis of the E-ring allylic stannane **3** started with the known optically active acetoxylalcohol **5**, which can be readily prepared from methylmalonic acid ester over six steps via the key enzymatic desymmetrization of *meso*-2,4-dimethyl-1,5-pentanediol (Scheme 2).¹⁰ At first, the hydroxy group was oxidized with IBX¹¹ and the aldehyde was treated with thiophenol and BF₃·OEt₂ to give the dithioacetal **6** in 83% yield. Removal of the acetyl group followed by oxidation provided aldehyde **7**, which in turn was reacted with the vinylic anion, generated from 2-bromopropen-1-ol¹² and *t*-BuLi. The reaction proceeded quite smoothly at

Scheme 2. Preparation of the E-Ring Allylic Stannane **3**



–78 °C to give diol **8** in 76% yield as a chromatographically inseparable, diastereomeric mixture (*R/S* = 1.2:1). We then enriched the desired (2*S*)-isomer. Thus, the four-step transformation, including (1) the temporary protection of the primary hydroxy group, (2) oxidation of the remaining hydroxy group by IBX, (3) stereoselective reduction of the ketone by using DIBAL-H, and (4) the removal of the TBDPS protecting group by TBAF, allowed enrichment of the diastereomeric ratio of **8** to *R/S* = 1:5.0.¹³ To construct the E-ring tetrahydropyran, **8** was next treated with BF₃·OEt₂ in CH₂Cl₂. The (2*S*)-isomer preferentially reacted to give **9** in 71% yield as a diastereomeric mixture at the acetal carbon center (2*R*/2*S* = 1:2.4), and the dithioacetal with unnatural (*R*) stereochemistry at the C₂₅ position was recovered and recycled for the same transformation again. Careful chromatographic separation of the alcohol **9** gave the pure (2*S*)-isomer, which was finally converted to the allylic stannane (2*S*)-**3**, the E-ring fragment, by bromination followed by stannylation (Bu₃SnLi, CuBr).¹⁴

The synthesis of the FGHI-ring fragment, corresponding to the C₂₈–C₄₀ position, was next explored. The stereoselective construction of the unique azaspiro HI-ring is the major concern in this synthesis. Our first-generation synthesis employed the Boc protecting group for the C₄₀–amino functionality.⁷ However, a partial decomposition of the Boc group was observed under the conditions for the HI-ring formation using Yb(OTf)₃. Here, we decided to explore an

(6) Nicolaou, K. C.; Frederick, M. O.; Petrovic, G.; Cole, K. P.; Loizidou, E. *Z. Angew. Chem., Int. Ed.* **2006**, *45*, 2609.

(7) Sasaki, M.; Iwamuro, Y.; Nemoto, J.; Oikawa, M. *Tetrahedron Lett.* **2003**, *44*, 6199.

(8) For synthetic studies on the E-, F-, G-, H-, and/or I-ring domain of **1**, see: (a) Carter, R. G.; Weldon, D. J. *Org. Lett.* **2000**, *2*, 3913. (b) Aiguade, J.; Hao, J. L.; Forsyth, C. J. *Org. Lett.* **2001**, *3*, 979. (c) Aiguade, J.; Hao, J. L.; Forsyth, C. J. *Tetrahedron Lett.* **2001**, *42*, 817. (d) Forsyth, C. J.; Hao, J. L.; Aiguade, J. *Angew. Chem., Int. Ed.* **2001**, *40*, 3663. (e) Zhou, X. T.; Carter, R. G. *Chem. Commun.* **2004**, 2138. (f) Zhou, X. T.; Carter, R. G. *Angew. Chem., Int. Ed.* **2006**, *45*, 1787. (g) Nguyen, S.; Xu, J.; Forsyth, C. J. *Tetrahedron* **2006**, *62*, 5338.

(9) Evans, D. A.; Trotter, B. W.; Coleman, P. J.; Cote, B.; Dias, L. C.; Rajapakse, H. A.; Tyler, A. N. *Tetrahedron* **1999**, *55*, 8671.

(10) (a) Lin, G. Q.; Xu, W. C. *Tetrahedron* **1996**, *52*, 5907. (b) Fujita, K.; Mori, K. *Eur. J. Org. Chem.* **2001**, 493.

(11) Frigerio, M.; Santagostino, M. *Tetrahedron Lett.* **1994**, *35*, 8019.

(12) Li, K. Q.; Du, W. S.; Que, N. L. S.; Liu, H. W. *J. Am. Chem. Soc.* **1996**, *118*, 8763.


(13) The stereochemistry of these products was determined by the modified Mosher ester analysis of undesired (*R*)-**8**, which was obtained by recrystallization.

(14) (a) Piers, E.; Chong, J. M.; Gustafson, K.; Andersen, R. J. *Can. J. Chem.* **1984**, *62*, 1. (b) Williams, D. R.; Plummer, S. V.; Patnaik, S. *Angew. Chem., Int. Ed.* **2003**, *42*, 3934.

alternative, stable protecting group, which also supports the stereoselective cyclization of the azaspiro ring.

The 2-nitrobenzenesulfonyl (nosyl, Ns) group¹⁵ was at first employed because it is electron withdrawing and hence is expected to promote the spiroaminal formation smoothly (Scheme 3). However, the reaction on **10**¹⁶ by using Yb-

Scheme 3. Spiroaminal Formation Leading to an Unnatural Isomer^a




^a Dashed arrows indicate the NOESY correlations observed.

(OTf)₃ was found to be very slow at room temperature, and the stereochemistry of the product **11**, obtained in 25% as the sole product, was inconsistent with that of the natural azaspiracid-1 (**1**). That is, from the NOEs observed at H₃₅-(pro-*S*)/C₃₇-Me and H₃₅(pro-*S*)/H₃₈ax, the stereochemistry at C₃₆ was determined to be *R*, which is not desired. When BF₃·OEt₂ was used for the Lewis acid, the cyclization proceeded quite smoothly in 89% yield, but the stereoselectivity was not improved.¹⁷

We next examined the alkylcarbamate protecting group, which is more stable than the Boc group previously used for the C₄₀-amino functionality.⁷ The alcohol **12**⁷ was at first protected, and a 2-nosylamino group was introduced to the C₄₀ position by desilylation with TBAF and the Mitsunobu reaction,¹⁸ to afford **13** in 78% overall yield (Scheme 4). After the amide was allyloxycarbonylated (Alloc), the Ns group was removed by the Fukuyama protocol using 2-mercaptoethanol to give **14**. Then, the H-ring moiety was constructed by successive deprotection of the MOM¹⁹ and the dithiane groups,²⁰ followed by the furanose formation in MeOH to give **15** in 28% yield (47% based on recovered materials) for three steps. At this time, the Alloc protecting group was hydrogenated with a less acidic catalyst²¹ to provide the propyl carbamate **16** in 91% yield, ready for the next crucial cyclization. The reduction was necessary for the selective removal of the benzyl groups at the C₂₈, C₃₂, and C₃₄ positions later.²² With the cyclization precursor **16** in hand, Yb(OTf)₃-catalyzed spiroaminal formation^{8d} was at-

Scheme 4. Preparation of the C₂₈-C₄₀ FGHI-Ring Domain **4** with Correct Spiroaminal Stereochemistry^a



^a Dashed arrow indicates the NOESY correlations observed.

tempted in CH₂Cl₂ at 0 °C. As expected, the cyclization proceeded smoothly in 1 h, to give spiroaminal **17** in 78% yield. The cyclization was highly stereoselective, and the stereochemistry at the spirocenter was unambiguously determined to be identical to that of the natural **1** by the NOE at H₃₅(pro-*R*)/C₃₇-Me. The spiroaminal **17** was further converted to alcohol **18** by protecting group manipulations, which was then oxidized by tetrapropylammonium perruthenate (TPAP)²³ to give aldehyde **4** for the coupling with the E-ring fragment **3** in 71% yield over four steps.

With the key fragments **3** and **4** in hand, their coupling reactions leading to the desired EFGHI-ring domain were next explored. In our first-generation synthesis, where simple

(15) (a) Fukuyama, T.; Jow, C. K.; Cheung, M. *Tetrahedron Lett.* **1995**, 36, 6373. (b) Kan, T.; Fukuyama, T. *Chem. Commun.* **2004**, 353.

(16) Prepared from **12** in 54% yield over five steps.

(17) The stereoselectivity observed in the spiroaminal formation was unexpected but was reasonably explained by calculation at the MMFF94S force field. The details will be reported in the full account of this work.

(18) Henry, J. R.; Marcin, L. R.; McIntosh, M. C.; Scola, P. M.; Harris, G. D.; Weinreb, S. M. *Tetrahedron Lett.* **1989**, 30, 5709.

(19) Hanessian, S.; Delorme, D.; Dufresne, Y. *Tetrahedron Lett.* **1984**, 25, 2515.

(20) Stork, G.; Zhao, K. *Tetrahedron Lett.* **1989**, 30, 287.


(21) Sajiki, H.; Ikawa, T.; Hirota, K. *Tetrahedron Lett.* **2003**, 44, 7407.

(22) An alkyl carbamate protecting group can be generally removed with various nucleophiles; see: (a) Tius, M. A.; Kerr, M. A. *J. Am. Chem. Soc.* **1992**, 114, 5959. (b) Wenkert, E.; Hudlicky, T.; Showalter, H. D. H. *J. Am. Chem. Soc.* **1978**, 100, 4893. (c) Corey, E. J.; Weigel, L. O.; Floyd, D.; Bock, M. G. *J. Am. Chem. Soc.* **1978**, 100, 2916.

(23) Griffith, W. P.; Ley, S. V.; Whitcombe, G. P.; White, A. D. *J. Chem. Soc. Chem. Commun.* **1987**, 1625.

methallyl stannane was used as a preliminary study, $\text{MgBr}_2 \cdot \text{OEt}_2$ was employed for this coupling.⁷ However, it was found from another preliminary model study using more complex allylic stannane **19**²⁴ that neither $\text{MgBr}_2 \cdot \text{OEt}_2$ nor LiClO_4 worked for this coupling reaction, only recovering the substrates (Table 1, runs 1 and 2). More reactive $\text{BF}_3 \cdot \text{OEt}_2$

Table 1. Preliminary Model Studies for the Coupling of **4** with Allylic Stannane **19**



run	conditions	yield for 20 (%) / recovery of 4 (%)
1	$\text{MgBr}_2 \cdot \text{OEt}_2$ (4.0 equiv), CH_2Cl_2 , -20°C	0/56
2	LiClO_4 (3.0 equiv), Et_2O , rt	0/95
3	$\text{BF}_3 \cdot \text{OEt}_2$ (2.0 equiv), MS4A, CH_2Cl_2 , -78°C	0/<30
4	InCl_3 (3.0 equiv), acetone, rt	0/88
5	InCl_3 (3.0 equiv), THF, rt	100/—


induced decomposition even at -78°C (run 3). From the ^1H NMR spectra of the product mixture, the decomposition was supposed to occur at the HI-ring azaspiro moiety. To avoid the decomposition, we investigated another Lewis acid, which would hopefully work in a Lewis basic solvent. It was then found that, when InCl_3 was used in acetone, the allylic stannane **19** reacted with acetone cleanly (run 4).²⁵ We therefore explored other solvents, and THF was finally found to be satisfactory to give the desired product **20** in a quantitative yield (run 5). With this protocol using InCl_3 (3.0 equiv) in THF, the coupling reaction between the key

(24) The allylic stannane **19** was prepared from 2-bromo-3-trimethylsilylpropene in 37% yield over nine steps. See the Supporting Information. The details will be given in the full account of this work.

(25) Marshall, J. A.; Hinkle, K. W. *J. Org. Chem.* **1995**, 60, 1920.

fragments **3** (5.6 equiv) and **4** (1.0 equiv) also proceeded smoothly at room temperature to give **21**, which has the C_{21} – C_{40} entire chain of azaspiracid (**1**) with complete functionalities, in 88% yield (Scheme 5). After mild oxidation with

Scheme 5. Synthesis of the EFGHI-Ring Fragment of Azaspiracid-1 (**1**)



IBX, the FG-ring was stereoselectively constructed upon exposure to $\text{HF} \cdot \text{pyridine}$, which induced desilylation and intramolecular acetalization, to give the desired EFGHI-ring fragment **2** of azaspiracid-1 (**1**) in 26% yield. The stereochemistry was unambiguously confirmed by NOESY experiments (see the Supporting Information).

In summary, we have successfully synthesized the suitably protected, lower half C_{21} – C_{40} fragment **2** of azaspiracid-1 (**1**) in 0.025% yield for the longest linear pathway from D-glutamic acid (37 steps). The synthesis features (1) stereoselective construction of the HI-ring spiroaminal and (2) high-yield coupling of the C_{21} – C_{27} and C_{28} – C_{40} fragments by allylic stannane chemistry. Work is in progress toward the total synthesis of **1** in our laboratory.

Acknowledgment. We thank Mr. Kitago of our laboratory for assistance with the experiment. Financial support was provided by the Novartis Foundation (Japan) for the Promotion of Science and by the Suntory Institute for Bioorganic Research. We also acknowledge a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, Culture and Technology, Japan.

Supporting Information Available: Experimental details and spectroscopic data for all new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL0613766